Related by context. All words. (Click for frequent words.) 78 achieve statistical significance 72 statistically significant 65 nonsignificant 65 statistical significance 65 attain statistical significance 63 multivariate adjustment 62 achieved statistical significance 62 virologic failure 62 prespecified 61 P = .# 61 statistically significant p = 60 HbA1c levels 60 postintervention 60 LVEF 60 morphometric vertebral fractures 59 diastolic heart 59 subgroup analyzes 59 HbA 1c 59 noninferiority 59 p = NS 59 LV dysfunction 59 nondiabetic patients 59 definite stent thrombosis 59 β blockers 59 HbA 1c levels 59 advanced adenomas 59 p = #.# [002] 58 periprocedural 58 Thal Dex 58 statistically significant differences 58 nonresponders 58 lumbar spine BMD 58 pCR 58 beta blocker therapy 58 Kaplan Meier analysis 58 univariate analysis 58 CC genotype 58 nonfatal MI 58 recurrent VTE 58 achieve sustained virologic 57 biochemical recurrence 57 endometrial thickness 57 CI -#.# 57 progression TTP 57 preoperative chemotherapy 57 MMSE score 57 prospectively defined 57 MACCE 57 colorectal adenoma 57 advanced adenoma 57 symptomatic intracerebral hemorrhage 57 multivariable analysis 57 CVD mortality 57 nonrandomized 57 median PFS 57 tirofiban 57 cabazitaxel 57 reinfarction 57 androgen deprivation 57 HBeAg negative patients 57 p = 57 QTcF 57 FOLFOX4 57 imatinib therapy 57 statistically nonsignificant 57 eplerenone 57 Subgroup analysis 57 PASI scores 57 TEAEs 57 heavily pretreated 57 tertile 57 virologic response 57 mL/min/#.# m 2 57 eptifibatide 57 bezafibrate 57 myocardial infarctions 57 ABC/3TC 57 cardiovascular mortality 56 primary endpoint 56 confidence interval CI 56 abciximab 56 posttreatment 56 #.#/#.# mmHg [001] 56 NIHSS score 56 Ishak fibrosis score 56 DMARD 56 neurologic progression 56 XIENCE V demonstrated 56 Subgroup analyzes 56 TNF blocker therapy 56 oxycodone CR 56 ipsilateral stroke 56 achieved ACR# 56 multivariate Cox 56 placebo 56 CR nPR 56 ALLHAT 56 iniparib 56 locoregional recurrence 56 confidence interval #.#-#.# 56 systolic dysfunction 56 5-FU/LV 56 p = .# [002] 56 pioglitazone 56 intravesical therapy 56 binary restenosis 56 NEVO ™ 56 XELOX 56 NYHA class 56 aminotransferases 56 placebo p = 56 anthracycline containing 56 lipid lowering drugs 56 Baseline characteristics 56 carotid IMT 56 serum calcium 56 serum urate 56 ejection fractions 56 intima media thickness 56 posttransplant 56 severe hypoglycemic 56 liver histology 56 hemoglobin A1c levels 56 subclinical hyperthyroidism 55 SNP rs# [002] 55 NYHA functional class 55 lymph node involvement 55 LV ejection fraction 55 peginterferon alfa 2b 55 secondary endpoint 55 cerebrovascular events 55 clinically meaningful 55 serum creatinine levels 55 univariate 55 coinfected patients 55 TDF FTC 55 HCV RESPOND 2 55 VADT 55 platelet reactivity 55 NATRECOR ® 55 APTIVUS r 55 sustained virologic response 55 leukopenia 55 hippocampal volume 55 ACUITY trial 55 CLA supplementation 55 montelukast 55 systolic BP 55 #mg QD [001] 55 metformin monotherapy 55 VT VF 55 NNRTI resistance 55 carotid intima media 55 serum vitamin D 55 methotrexate monotherapy 55 noncarriers 55 paricalcitol 55 KRAS mutations occur 55 relapsers 55 6MWD 55 nicardipine 55 arterial thromboembolic events 55 stage IIIb IV 55 VaD 55 HbA1C levels 55 heterozygotes 55 QTc 55 infarct size 55 intact parathyroid hormone 55 symptomatic VTE 55 % Confidence Interval 55 pentoxifylline 55 MADRS score 55 irbesartan 55 nmol liter 55 virologically 55 Median survival 55 ATACAND 55 perioperative complications 55 % CI #.#-#.# [003] 55 comparator arm 55 hypercalcemia 55 genotypic resistance 55 μmol L 55 statistical significance p 54 squamous cell histology 54 baseline HbA1c 54 EGFR mutations 54 solifenacin 54 recurrent ischemia 54 NPH insulin 54 peginterferon 54 hip BMD 54 % CI #.#-#.# [007] 54 levosimendan 54 univariate analyzes 54 NIHSS 54 poorer prognosis 54 mCRC patients 54 candesartan 54 PSADT 54 extrapyramidal symptoms 54 completely resected 54 creatinine levels 54 posaconazole 54 non inferiority 54 % CI #.#-#.# [002] 54 locoregional 54 tapentadol ER 54 AUC0 54 hematologic toxicity 54 primary efficacy endpoint 54 RLAI 54 timepoint 54 MMSE scores 54 LEXIVA r 54 FOLFIRI 54 p = #.# [004] 54 carotid stenosis 54 sustained virological response 54 proteinuria 54 histologic 54 Folfox 54 biochemical relapse 54 MetS 54 distant metastases 54 mcg QD 54 Doxil ® 54 postop 54 secondary efficacy endpoints 54 urate levels 54 placebo fluoxetine 54 neurocognitive function 54 unfractionated heparin 54 multivariable adjusted 54 EpCAM expression 54 lamotrigine 54 renal insufficiency 54 lispro 54 esophageal carcinoma 54 AGILECT R 54 tiotropium 54 Multivariate analyzes 54 statistically significant improvement 54 disease progression 54 CI #.#-#.# [002] 54 QTc prolongation 54 lymphocytosis 54 tolvaptan 54 umol L 54 mg kg dose 54 fasting insulin 54 postoperative AF 54 selenium supplementation 54 clinicopathological features 54 serum concentrations 54 ischemic lesions 54 Bonferroni correction 54 revascularization procedures 54 methotrexate therapy 54 hippocampal atrophy 54 nonmetastatic 54 tipranavir r 54 infliximab 54 FEV1 54 pulmonary exacerbations 54 HOMA IR 54 microalbuminuria 54 #mg BID [001] 54 endoscopic remission 54 Hb A1C 54 CCyR 54 graft occlusion 54 highest tertile 54 KRAS mutant tumors 54 preintervention 54 colorectal adenomas 54 recurrent venous thromboembolism 54 Flu Cy 54 nonsignificant difference 54 ticagrelor 54 HER2 expression 54 nonvertebral fractures 54 normotensive 54 virological response 54 etanercept 54 dapagliflozin plus 53 estrogen receptor negative 53 ziprasidone 53 desvenlafaxine succinate 53 bosentan 53 prednisone prednisolone 53 insulin glargine 53 serum phosphate levels 53 placebo controlled trials 53 CTEPH 53 HIV HCV coinfected 53 tumor histology 53 timepoints 53 rolofylline 53 anemia hemoglobin 53 radiochemotherapy 53 squamous histology 53 beta carotene supplementation 53 nonfatal stroke 53 coronary revascularization 53 lipid lowering medications 53 left ventricular systolic 53 bronchopulmonary dysplasia 53 sotalol 53 IV bisphosphonates 53 doxorubicin docetaxel 53 Univariate analysis 53 HBeAg seroconversion 53 KIF6 carriers 53 hypertensives 53 underwent resection 53 CHD mortality 53 placebo p 53 intraobserver 53 parkinsonian symptoms 53 serum PSA 53 glargine 53 moderate renal impairment 53 adenoma recurrence 53 abatacept 53 cytogenetic abnormalities 53 subanalysis 53 FOLFOX 53 substudy 53 interferon alfa 53 recurrent glioblastoma multiforme 53 liver metastasis 53 antiretroviral naïve 53 androgen suppression 53 lipid lowering therapy 53 annualized relapse 53 incomplete revascularization 53 trastuzumab 53 nmol L 53 antibody titer 53 nonsignificant trend 53 aldosterone antagonists 53 clazosentan 53 Stent thrombosis 53 placebo dexamethasone 53 lung metastasis 53 corrected QT interval 53 laboratory abnormalities 53 revascularizations 53 HBeAg negative 53 anagrelide 53 statistically significant reduction 53 stage IIIB 53 tertiles 53 sirolimus stent 53 neutrophil counts 53 #ng/ml 53 fosamprenavir 53 paclitaxel eluting stents 53 thromboembolic events 53 metastatic lung cancer 53 coinfected 53 chlorambucil 53 troponin T 53 efficacy endpoint 53 left ventricular dysfunction 53 SUVmax 53 dalteparin 53 complete cytogenetic response 53 sunitinib 53 noncardiac 53 DES implantation 53 IFN alfa 53 serum cholesterol 53 PANSS scores 53 GOUT 53 distant metastasis 53 HNSCC 53 unmeasured confounders 53 HCV SPRINT 53 adjuvant chemotherapy 53 EGFR mutation positive 53 Stage IIIb 53 mcg albinterferon alfa 2b 53 fructosamine 53 alteplase 53 NYHA Class II 53 NSABP C 53 hsCRP levels 53 thiazide diuretics 53 femoral neck BMD 53 Secondary endpoints included 53 antiretroviral naive 53 rimonabant #mg 53 nodal metastases 53 hemoglobin A1c HbA1c 53 pg ml 53 infarcts 53 tamsulosin 53 noninferior 53 dexrazoxane 53 serum BDNF 53 Operative mortality 53 pamidronate 53 isolated systolic hypertension 53 tumor shrinkage 53 fluvastatin 53 citalopram 53 thromboembolism 53 anthracycline taxane 53 echocardiographic parameters 53 prostate cancer CaP 52 periprocedural MI 52 hormone receptor negative 52 active comparator 52 pT3 52 A1c levels 52 lymphadenectomy 52 thromboembolic 52 GH deficiency 52 baminercept 52 preoperative PSA 52 subclinical hypothyroidism 52 DMARDs 52 osteopenic 52 valsartan 52 EDSS score 52 thromboembolic complications 52 Elitek 52 residual confounding 52 discontinuations due 52 postoperative complications 52 SLNB 52 metastatic RCC 52 ± SD 52 EBRT 52 % CI #.#-#.# [006] 52 nadroparin 52 nondiabetics 52 rs# [004] 52 gout flares 52 arterial thickening 52 LPV r 52 ribavirin therapy 52 SHBG levels 52 FDA defined valvulopathy 52 diuretic chlorthalidone 52 XIENCE V PROMUS Stent 52 neoadjuvant chemotherapy 52 thyrotropin levels 52 mg dose 52 free survival PFS 52 p = #.# [003] 52 IL#B 52 serum urate levels 52 salmeterol fluticasone 52 PSA nadir 52 demonstrated statistically significant 52 ibandronate 52 Dose escalation 52 statistically significant p 52 coronary stenosis 52 experienced virologic failure 52 coronary calcification 52 elevated LDH 52 postoperative bleeding 52 antipsychotic efficacy 52 β blocker 52 virologic 52 divalproex 52 creatinine ratio 52 liver transaminases 52 lopinavir r arm 52 perimenopausal women 52 SGRQ 52 undergoing coronary angiography 52 CIMZIA TM certolizumab pegol 52 Hazard Ratio HR 52 tumor recurrence 52 angiographic restenosis 52 interferon alfa 2b 52 elevated ALT 52 adjuvant radiotherapy 52 mammographic density 52 tHcy 52 T2DM 52 renal dysfunction 52 QTc interval 52 ramipril 52 interquartile range 52 HBeAg 52 pericardial effusion 52 generalizability 52 CrCl 52 pyridostigmine 52 hepatotoxicity 52 TOP2A 52 ketorolac 52 multivariate analyzes 52 HER2 positive cancers 52 hemoglobin concentration 52 mitoxantrone 52 secondary efficacy endpoint 52 secondary endpoints 52 diastolic dysfunction 52 mutated KRAS 52 perioperatively 52 overt hypothyroidism 52 postoperative complication 52 postoperative mortality 52 colorectal neoplasia 52 protein excretion 52 cilostazol 52 mITT 52 left ventricular ejection 52 #mmHg [001] 52 nonalcoholic steatohepatitis NASH 52 plus MTX 52 mycophenolic acid 52 KRAS mutations 52 Telintra 52 urate lowering therapy 52 adalimumab 52 glycated hemoglobin HbA1c 52 seropositivity 52 pegylated interferon alfa 2b 52 comorbidities 52 ezetimibe simvastatin 52 chemoradiotherapy 52 p ≤ 52 #mg dose [003] 52 microbiologically evaluable 52 perioperative mortality 52 macroalbuminuria 52 ACTEMRA TM 52 femoral neck fracture 52 preserved ejection fraction 52 tranylcypromine 52 intracerebral haemorrhage 52 sirolimus eluting stents 52 oxcarbazepine 52 splenectomized patients 52 amisulpride 52 psychiatric comorbidity 52 NNT = 52 severe exacerbations 52 hemorrhagic complications 52 insulin detemir 52 coadministration 52 polyp recurrence 52 invasive aspergillosis 52 atheroma volume 52 lowest tertile 52 certolizumab 52 elevated troponin 52 urinary N telopeptide 52 Free Survival PFS 52 receiving prophylactic anticoagulation 52 placebo controlled clinical 52 erlotinib 52 stent thromboses 52 serum IGF 52 concomitant medications 52 nonoperative 52 composite endpoint 52 ARB telmisartan 52 undetectable HBV DNA 52 receiving golimumab 52 Winkelmayer 52 severe hypoglycemia 52 carvedilol 52 comorbidity 52 adjuvant therapies 52 bendamustine 52 oral antidiabetic agents 52 null responders 52 Cmax 52 nonischemic 52 prior chemotherapy regimens 52 multivariate analysis 52 PCa 52 SORT OUT III 52 decompensated cirrhosis 52 familial clustering 52 nonischemic cardiomyopathy 52 thrombotic events 52 thyroid carcinoma 52 neurocognitive deficits 52 non squamous histology 52 primary efficacy endpoints 52 rs# [002] 52 tumor progression TTP 52 clinically meaningful differences 52 IOP lowering 52 NATRECOR R 52 anti TNF 52 confounding variables 52 ertapenem 52 cardiovascular morbidity 52 MDRD 52 avosentan 52 Multivariate analysis 52 FOLFIRI alone 52 advanced neoplasia 52 QTc intervals 52 mineral density 52 NAbs 52 prognostic factors 52 leukocyte count 52 acutely decompensated congestive heart 52 gout flare 51 OADs 51 systolic blood pressures 51 pemetrexed 51 reoperation 51 ribavirin RBV 51 events TEAEs 51 detectable HCV RNA 51 Postoperatively 51 n = 51 serum phosphate 51 peginterferon alfa 2a 51 lymph node metastasis 51 AST ALT 51 #.#ng/ml 51 elevated bilirubin 51 MGUS 51 evaluable 51 nelfinavir 51 TNF inhibitor 51 metabolic parameters 51 hyperacute 51 ADAS Cog 51 GBA mutations 51 CsA 51 sulphonylureas 51 microbiological eradication 51 preoperative 51 P ≤ 51 vertebral fracture 51 visceral metastases 51 bosutinib 51 elevated transaminases 51 correlational 51 interferon therapy 51 #.#mg/dL 51 shorter telomere length 51 histologic subtype 51 plasma leptin 51 everolimus eluting stents 51 plus dexamethasone 51 serum phosphorous 51 fondaparinux 51 eribulin 51 glycated hemoglobin levels 51 interferon gamma 1b 51 postoperative radiotherapy 51 pegylated interferon 51 fasting glucose levels 51 PCWP 51 plus COPEGUS 51 FOLPI 51 tibolone 51 autonomic dysfunction 51 gastric carcinoma 51 extracapsular extension 51 azacitidine 51 cisplatin vinorelbine 51 cryptogenic 51 receiving ISENTRESS 51 renal toxicity 51 carotid plaque 51 ventricular remodeling 51 plasma uric acid 51 idraparinux 51 serum sodium 51 TT genotype 51 QT intervals 51 hypoglycemic events 51 plus prednisone 51 GnRH agonist 51 prespecified secondary 51 airway responsiveness 51 virological failure 51 brain metastases 51 Lucentis monotherapy 51 randomized trials 51 ZOLINZA 51 hematologic adverse 51 Perforomist Inhalation Solution 51 severe neutropenia 51 pulmonary exacerbation 51 adefovir 51 viral kinetics 51 TNF antagonist 51 asthma exacerbations 51 vasogenic edema 51 hyperalgesia 51 adjunctive placebo 51 -#.# log# 51 PRIMO CABG2 51 leucopenia 51 alanine aminotransferase ALT 51 ventricular tachyarrhythmia 51 DLTs 51 prognostic significance 51 adjuvant therapy 51 aromatase inhibitor therapy 51 silent ischemia 51 STRIDE PD 51 riociguat 51 interobserver reliability 51 endometrial hyperplasia 51 docetaxel pretreated 51 ADAS cog 51 DAPT 51 enalapril 51 pegIFN 51 recurrent genital herpes 51 undetectable viral loads 51 Xelox 51 Taxus Stent 51 albumin excretion rate 51 lipid parameters 51 atazanavir ritonavir 51 alanine aminotransferase 51 mIU L 51 undergoing CABG 51 T2 lesions 51 hydroxyvitamin D levels 51 Montgomery Åsberg Depression 51 antihypertensive therapy 51 febrile neutropenia 51 clinically insignificant 51 noncardiovascular mortality 51 detrusor overactivity 51 raltegravir 51 SVR# 51 unresectable 51 antihypertensive medications 51 enoximone 51 dose statin therapy 51 trastuzumab Herceptin ® 51 biopsy Gleason 51 HAQ DI 51 mg d 51 estimated GFR 51 ruboxistaurin 51 paroxysmal AF 51 flow mediated dilation 51 cortical thickness 51 relapsed MM 51 serum ALT 51 serum estradiol 51 salmeterol HFA MDI 51 white matter hyperintensities 51 intima media thickness IMT 51 clopidogrel 51 gefitinib 51 NP CRNs 51 tolterodine 51 cystectomy 51 glomerular filtration rate 51 vicriviroc 51 ICD therapy 51 HbA1c 51 creatinine clearance 51 cytotoxic therapy 51 cirrhotic patients 51 diastolic function 51 neoplasias 51 lipid profiles 51 apolipoprotein B 51 HbA 1C 51 hypoglycemic episodes 51 serum calcium levels 51 CYP#D# inhibitor 51 HCV genotype 1 51 pT2 51 PREZISTA r arm 51 apremilast 51 chlorthalidone 51 infliximab monotherapy 51 clinicopathological 51 zoledronic acid 51 PNH patients 51 ocrelizumab 51 seroconversion 51 atherosclerotic renal artery stenosis 51 clinically evaluable 51 deep venous thromboses 51 CYPHER Stent 51 intestinal metaplasia 51 plasma glucose levels 51 rt PA 51 CIN3 51 CLBP 51 drank colas 51 4mg/kg 51 % CI #.#-#.# [001] 51 abacavir lamivudine 51 syncopal 51 hepatocellular carcinomas 51 confounders 51 chlamydial infection 51 demonstrated clinically meaningful 51 KRAS wild 51 cancer mCRC 51 TACE 51 decitabine 51 viraemia 51 neostigmine 51 recurrent DVT 51 Carotid Revascularization Endarterectomy vs. 51 CD4 cell 51 bladder carcinoma 51 nonobese 51 primary endpoints 51 perineural invasion 51 UACR 51 clodronate 51 cangrelor 51 K ras mutations 51 sorafenib Nexavar 51 MELD scores 51 coinfection 51 dobutamine 51 oral corticosteroid 51 reoperations 51 HDRS 51 mmol l 51 intravenous cyclophosphamide 51 BENICAR HCT 51 pregabalin 51 #mg/day [001] 51 highly emetogenic 51 intensive statin therapy 51 limiting toxicity 51 mucosal healing 51 p = .# [001] 50 μg kg 50 prolonged QT interval 50 cerebral infarction 50 flutamide 50 baseline CD4 50 nonoperative treatment 50 proliferative diabetic retinopathy 50 anti HBs 50 sUA 50 unblinded 50 sorafenib 50 BH4 50 intravenous bisphosphonates 50 dexamethasone Decadron 50 IR prednisone 50 DAS# remission 50 mg QD 50 metastatic castration resistant 50 octreotide LAR 50 depressive symptomatology 50 estramustine 50 seronegative 50 ipsilateral 50 SCr 50 Plasma concentrations 50 protease inhibitor mutations 50 albumin excretion 50 DAS# CRP 50 triglyceride concentrations 50 elevated CRP 50 median CD4 50 subthreshold depression 50 sirolimus eluting stent 50 aortic regurgitation 50 chemoradiation 50 medically inoperable 50 ALSFRS R 50 QRS duration 50 MERLIN TIMI 50 lymph node metastases 50 CIMZIA ™ 50 pegaptanib 50 achieved sustained virological 50 subgroup 50 olmesartan 50 somatostatin analog 50 rizatriptan 50 sustained ventricular tachycardia 50 HCV genotype 50 enoxaparin 50 bacteriuria 50 mcg BID 50 intracerebral hemorrhage 50 thienopyridines 50 tamoxifen therapy 50 exemestane 50 repeat revascularization 50 serum magnesium 50 metastatic malignant melanoma 50 plus ribavirin 50 pneumonectomy 50 tolterodine ER 50 EXJADE 50 nonadherence 50 postoperative chemotherapy 50 circulating endothelial cells 50 underwent coronary angiography 50 colorectal polyp 50 hepatitis C genotype 50 NYHA Class III 50 voriconazole 50 cardiac dysfunction 50 dopaminergic therapy 50 sumatriptan naproxen sodium 50 acute bronchospasm 50 carotid plaques 50 HBeAg positive 50 mITT population 50 histopathological 50 UPDRS scores 50 pressor response 50 venlafaxine XR 50 Median PFS 50 liver transplant recipients 50 KRAS mutation 50 colorectal tumors 50 benazepril 50 logistic regression models 50 df = 50 anakinra 50 micrometastases 50 mcg dose 50 carotid artery intima media 50 impair fertility 50 ximelagatran 50 receiving VICTRELIS 50 neurologic complications 50 statin therapy 50 ovarian carcinoma 50 immune reconstitution 50 conventional antipsychotics 50 cediranib 50 elevated liver enzymes 50 ABCB1 50 subcutaneous insulin 50 spine BMD 50 donepezil 50 PRIMO CABG 50 prospectively stratified 50 dyssynchrony 50 placebo controlled studies 50 androgen ablation 50 nondepressed 50 colorectal liver metastases 50 delayed gastric emptying 50 non squamous NSCLC 50 HbA1C 50 Pred Forte 50 POAG 50 g dL 50 maximal doses 50 specific antigen PSA 50 mg p = 50 neuropsychiatric symptoms 50 dasatinib 50 CD4 + cell 50 NHANES III 50 dose escalation 50 mg kg Hematide 50 spontaneous preterm delivery 50 euthyroid 50 adriamycin 50 lipid lowering agents 50 arterial occlusion 50 lamivudine refractory patients 50 pretest probability 50 IIIa inhibitor 50 confirmatory clinical 50 lymphopenia 50 celecoxib 50 rechallenge 50 cytopenias 50 mycophenolate mofetil 50 resected pancreatic cancer 50 HF hospitalization 50 dosing cohort 50 antiplatelet therapy 50 UGT#A# * 50 corticosteroid therapy 50 tocilizumab 50 eosinophil count 50 surrogate endpoint 50 APTIVUS 50 highest quintile 50 imply causality 50 pg mL 50 unfavorable cytogenetics 50 #mg/day [002]